NCT03391778 Adoptive Cell Therapy Long-term Follow-up (LTFU) Study
| NCT ID | NCT03391778 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | USWM CT, LLC |
| Condition | Neoplasms |
| Study Type | INTERVENTIONAL |
| Enrollment | 250 participants |
| Start Date | 2018-04-09 |
| Primary Completion | 2032-04-01 |
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This trial will evaluate long term safety of participants who have received AdaptImmune (ADP) adoptive cell therapy for up to 15 years following last adoptive cell therapy infusion.
Eligibility Criteria
Inclusion Criteria: * Participants who have received at least one dose of ADP adoptive cell therapy agent. * Participants who have completed ADP sponsored or supported interventional study or have withdrawn from it. * Participants who have completed treatment as part of managed access to a GSK adoptive cell therapy. * Contraceptive use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. * The investigator is responsible for review of medical history. * Capable of giving signed informed consent. Exclusion Criteria: \- None